-
April 12, 2013
Novartis' Alcon unit has launched Jetrea for an age-related progressive, sight-threatening condition in the UK, its first market
Full story
-
March 18, 2013
ThromboGenics and partner Novartis have got the green light from regulators in Europe for Jetrea for an age-related progressive, sight-threatening condition
Full story
-
March 13, 2013
Shire has continued its expansion into rare diseases by acquiring Sweden's Premacure, which is developing a treatment for a potentially blinding eye disorder that affects premature babies
Full story
-
January 21, 2013
The latest set of opinions from the European Medicines Agency includes recommendations for Pfizer's leukaemia drug Bosulif and ThromboGenics/Novartis' eye drug Jetrea
Full story
-
July 30, 2012
Shares in ThromboGenics have soared after regulators in the USA recommended approval for the Belgian firm's eye drug ocriplasmin
Full story
-
May 11, 2012
As the debate over off-label use is reignited following the publication of data on Roche's cancer blockbuster Avastin as a treatment for wet age-related macular degeneration, the European Alliance for Access to Safe Medicines is calling for urgent action to clarify when drugs can be used outside their approved status
Full story
-
March 30, 2012
A couple of weeks after signing a major deal with Novartis for its eye drug ocriplasmin, Belgium's ThromboGenics has raised 77.8 million euros through a private placement
Full story
-
March 22, 2012
Shares in NicOx have soared for the second time in a week after the French biotech bought a stake in the UK's Altacor, with an option to buy the privately-held ophthalmology company outright
Full story
-
February 29, 2012
European regulators have given their seal of approval for Alimera Science's Iluvien, three months after their counterparts in the USA once again rejected the treatment for diabetic macular oedema
Full story
-
January 19, 2012
Novartis has been given the thumbs-up in China to market its eye drug Lucentis and has also launched its diabetes treatment Galvus in the country
Full story